Clinical Research Directory

Inclusion Criteria: * Confirmed HCC based on histopathological findings from tumor tissues or radiologically findings. * Must not have received prior systemic therapy for unresectable HCC. * Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C. * Child-Pugh Score class A. * ECOG performance status of 0 or 1 at enrollment. * At least 1 measurable lesion per RECSIT 1.1 guidelines Exclusion Criteria: * Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Grade ≥2 from previous anticancer therapy. * History of hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy. * Clinically meaningful ascites. * Patients with main portal vein thrombosis. * Active or prior documented GI bleeding. * Patient currently exhibits symptomatic or uncontrolled hypertension. * Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV) * Uncontrolled intercurrent illness